Half Yearly Report and Accounts
Released
Released
Announcement PDF
ASX Announcement
Appendix 4D: Half Year Report
Current reporting period: Half-year ended 31 December 2024
Prior corresponding period: Half-year ended 31 December 2023
Results for announcement to the market
31 December 2024
$’000
31 December 2023
$’000
Movement %
Revenue
2,427
8,025
Down (70%)
Loss for the period attributable to members
(5,392)
(1,034)
Up (421%)
Adjusted Revenue1 (excluding Mundipharma settlement)
2,427
1,472
Up (65%)
Adjusted Loss1 (excluding Mundipharma settlement)
(5,392)
(7,587)
Down (29%)
Reported
Additional information – Operating Result
Note 1: The prior corresponding period included a nonrecurring $6,553,000 income item from the commercial settlement and
termination of the VivaGel® BV license and supply agreement with Mundipharma. Prior period Adjusted Revenue ($1,472,000) is
calculated as Revenue less nonrecurring revenue from the Mundipharma settlement. Prior period Adjusted Loss likewise subtracts the
above nonrecurring revenue from the Loss for the period.
Dividends
No dividends were paid or declared during the current period or during previous corresponding period.
Explanation of Revenue
Revenue for the half-year was $2,427,000, comprising product sales, royalty, and research revenue from
commercial partners of $1,888,000 (31 December 2023: $644,000, excluding the Mundipharma
settlement), and interest income on cash invested of $539,000 (31 December 2023: $828,000). For the
Operating Result, the half-year revenue has increased 65% over the prior period, primarily due to research
revenue from Petalion Therapeutics and increased revenue from the sale of Viraleze™ and VivaGel® BV.
Explanation of Loss
The loss for the half-year was $5,392,000 (31 December 2023: $7,587,000, excluding the Mundipharma
settlement). The Operating Result for the half-year loss has decreased 29% over the prior period.
The half-year loss includes research and product development expense of $4,337,000 (31 December 2023:
$5,263,000) net of the Australian Government’s R&D tax incentive. Research expenditures include costs of
the internal DEP® drug delivery programs including DEP® SN38, DEP® cabazitaxel and DEP® radiotheranostics.
The decrease in expense from the prior half-year reflects the completion of the DEP® cabazitaxel, DEP®
docetaxel, and Viraleze™ clinical programs.
Net Tangible Asset Backing
Net tangible asset (NTA) backing per ordinary share at 31 December 2024 is $0.06 (31 December 2023:
$0.08).
Additional information supporting the Appendix 4D can be found in the Interim Report for the half-year ended 31 December 2024 which
follows this announcement. The Interim Report has been reviewed by PricewaterhouseCoopers.
ASX Announcement
Interim Report and Half- Year Financial Results
Key Financial Results
•
Half-year revenues were $2.4 million, including research revenue from Petalion
Therapeutics and revenue from Viraleze™ and VivaGel® BV product sales.
•
The underlying operating loss was $5.4 million, a 29% improvement on the prior
corresponding period (pcp).
•
Research and development expenses were $4.3 million, decreasing by $0.9 million from
the pcp due to the completion of DEP® clinical programs in FY24.
•
Closing cash position at 31 December 2024 was $20.3 million.
Operational Highlights
•
Key regulatory milestone for DEP® SN38 with positive feedback from the FDA on the clinical
pathway to commercialisation in the US, confirming that the 505(b)(2) regulatory approval
pathway is appropriate for DEP® SN38 and the potential for Fast Track designation and
accelerated approval.
•
Continued progress in ongoing DEP® partnerships and expansion of the chemistry team to
support these collaborations.
•
Asset optimisation and active engagement with potential collaborators for the DEP®
radiopharmaceuticals program.
Melbourne, Australia; 26 February 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative
biotechnology company with two decades of experience in advancing dendrimer technology from
the lab to the patient, today releases its Interim Report and Half-Year Financial Results for the
period ended 31 December 2024 (H1 FY25).
Starpharma’s Chief Executive Officer, Cheryl Maley, commented:
"In the first half of FY25, Starpharma has made good progress in executing our strategy, aimed at
maximising the value of our DEP® assets, accelerating early asset development, and building longterm sustainability. I know our internal progress may not always be evident externally, but I can
vouch for the dedication and hard work of everyone at Starpharma as we work towards achieving
our strategic objectives.
“We have made important progress in advancing our DEP® clinical assets, particularly DEP® SN38,
which has shown promising clinical outcomes in patients with high unmet need. A key regulatory
milestone during the period was the recent meeting with the US Food and Drug Administration
(FDA) regarding DEP® SN38. The FDA provided feedback on the path to market for DEP® SN38,
confirming that the 505(b)(2) regulatory approval pathway is appropriate for DEP® SN38 and the
potential for Fast Track designation and accelerated approval. The positive response from the US
regulator increases our confidence in the potential of DEP® SN38 for treating platinum-resistant
ovarian cancer. During the six months to December, our partner engagement through ongoing
meetings and conference participation highlighted the importance of FDA feedback to potential
partners for the commercialisation of DEP® SN38.
“We are advancing our early-stage DEP® programs, particularly in the area of
radiopharmaceuticals, with the aim of initiating a first-in-patient clinical trial this calendar year.
We are also expanding our research pipeline, positioning us well for future collaborations and
long-term growth. Commercially, we anticipate the launch of VivaGel® BV in key markets in the
Middle East and continue to support sales of Viraleze™ online through digital marketing initiatives,
which have resulted in a ~30% increase in revenue from the e-commerce channels compared to
the prior corresponding period.
“We have focused on building a sustainable organisation and have sufficient capital to support
our medium-term objectives, with a cash balance of $20.3 million as at 31 December 2024. The
completion of multiple clinical programs in FY24 has led to a reduction in our research and
development expenses, extending our cash runway. Over the past 12 to 18 months, we have
implemented a number of cost-saving initiatives that are positively impacting our cash balance.
Notably, our Corporate and Administration costs in this half-year period have decreased by $0.5
million compared to the prior corresponding period.
“Starpharma is committed to driving revenue growth, advancing our pipeline, and managing costs
effectively to deliver improved and long-term value for our shareholders. We are focused on
prioritising resources for our high-impact DEP® programs, pursuing partnerships to advance our
assets toward commercialisation, and increasing revenue through collaborations, licensing and
product sales.”
About Starpharma
Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer
technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health
outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree
of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical
radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the Chair,
Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s
and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be
approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding
the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain
patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or
developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not
necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or
reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
2
Delivering
meaningful
patient outcomes
with advanced
dendrimer
technology
Interim Report
2025
Starpharma Holdings Limited
ABN 20 078 532 180
Interim Report
FOR THE HALF-YEAR ENDED 31 DECEMBER 2024
This information should be read in conjunction with the 30 June 2024 Annual Report and any public announcements made by
Starpharma Holdings Limited during the interim reporting period in accordance with the continuous disclosure requirements of
the Corporations Act 2001.
Contents
Directors’ Report
2
Auditor’s Independence Declaration
6
Interim Financial Report
7
Independent Auditor’s Review Report to the Members
16
Interim Report – 31 December 2024
Starpharma Holdings Limited
1
Directors’ Report
The directors are pleased to present this report on the consolidated entity (referred to hereafter as the “Group”, “Company”, or
“Starpharma”) consisting of Starpharma Holdings Limited (the “Parent Entity”) and the entities it controlled at the end of, or during,
the half-year ended 31 December 2024.
Directors
The following persons were directors of Starpharma Holdings Limited during the whole of the half-year and up to the date of this
report unless otherwise stated:
C Maley (Chief Executive Officer and Managing Director)
R B Thomas, AO (Chairman)
L Cheng
D J McIntyre
J R Davies
R Basser
Principal Activities
The principal activities of the Group consist of research, development and commercialisation of dendrimer products for
pharmaceutical and healthcare applications. Activities within the Group are directed towards the development of precisely
defined nano-scale materials, including the development of SPL7013 (astodrimer sodium) as a vaginal gel, VivaGel ® BV, for the
management of bacterial vaginosis; Viraleze™ antiviral nasal spray; and as an antiviral condom coating. Starpharma is also
applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP ®
(Dendrimer Enhanced Product) delivery platform.
Strategy, Future Developments and Prospects
The Company aims to generate value through the clinical development and commercialisation of its proprietary products, as well
as partnerships with pharmaceutical and biotechnology companies based on its patented dendrimer technology in
pharmaceutical and healthcare applications. Starpharma’s strategy involves three key focus areas to drive growth, extract value
from the dendrimer technology, and optimise shareholder returns: 1) maximise DEP® asset value; 2) accelerate early asset
development; and 3) build long-term sustainability. Starpharma intends to achieve this by continuing to utilise a combination of
internally funded and partnered projects across its dendrimer portfolio. The Company commercialises its development pipeline
with corporate partners through licensing, sales, and distribution agreements at various stages in a product’s development
lifecycle, depending on the product, patent opportunity, a partner’s commercial strategy and relative strength of product and
market expertise, comparison of current and future potential returns. Starpharma has extensive expertise in dendrimer science, a
strong intellectual property position, clinically validated technology, and a pipeline of products and partnerships at various
development stages designed to address unmet medical needs.
Dividends
No dividends have been paid or declared by the Company during the current reporting period. No dividends were paid for the
previous corresponding period.
Review of Operations
Maximising DEP® Asset Value
Starpharma’s three Phase 2 clinical trials for DEP® SN38, DEP® cabazitaxel, and DEP® docetaxel have generated significant data
and clinical validation for the company’s innovative dendrimer technology. Starpharma’s primary focus is to ensure that patients
with high needs have access to these improved drugs. Our key objective is to provide continued access to patients and to
successfully secure the most effective path to commercialisation.
DEP® SN38 (previously referred to as DEP® irinotecan) is Starpharma’s first priority, followed by DEP® cabazitaxel. Both assets
have demonstrated patient benefit in clinical trials, including promising efficacy and excellent tolerability. The Phase 2 results for
both assets were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024. Following these
results presentations, Starpharma's clinical and business development teams have worked diligently to enhance the product
profiles for potential partners interested in advancing these assets.
The promising results highlight the technology’s potential and have shown to be very important for companies looking to enhance
their drug development pipeline across a variety of drug types and therapeutic areas. An important aspect of Starpharma’s
business development program is to raise awareness about the benefits of Starpharma’s dendrimer technology in oncology and
other significant disease areas. As part of this strategy, the has company participated in a number of industry conferences over
the past six months to engage with clinicians and key decision-makers from potential partner organisations.
During the period, Starpharma met with the US Food and Drug Administration (FDA) to discuss the clinical pathway options for
DEP® SN38 in Platinum-Resistant Ovarian Cancer (PROC), which the FDA recognises as a patient group with significant unmet
need. The purpose of the meeting was to confirm the regulatory approval pathway and seek regulatory guidance on the design of
Interim Report – 31 December 2024
Starpharma Holdings Limited
2
a Phase 2/3 clinical program aimed at obtaining registration for DEP® SN38 in patients with platinum-resistant ovarian cancer in
the US.
During the meeting, the FDA agreed with Starpharma’s proposal that DEP® SN38 could be considered for FDA Fast Track
designation, acknowledging that PROC is a serious condition with significant unmet medical need. The FDA also agreed that a
“505(b)(2)” regulatory approval pathway is appropriate for DEP® SN38, as the product delivers the active moiety of the FDAapproved drug, irinotecan (Camptosar®). The 505(b)(2) pathway allows Starpharma to utilise existing FDA findings of safety and
efficacy for an already approved drug, potentially streamlining the approval process by removing the need for some additional
studies.
The FDA also indicated that DEP® SN38 may qualify for accelerated approval based on an interim analysis of early surrogate
endpoints from the proposed Phase 2/3 clinical program. Final outcomes will depend on the results of these studies and the
overall data package; however, this accelerated approval could provide early access to DEP® SN38 for patients with platinumresistant ovarian cancer.
During the meeting, the FDA offered valuable guidance on the study design, particularly in defining the target patient population,
study endpoints, and biostatistical aspects. The agency emphasised the importance of ensuring that DEP® SN38 is applicable to
a broad range of patients with platinum-resistant ovarian cancer.
Overall, the feedback and collaborative discussions with the FDA reflect a positive and constructive interaction for Starpharma,
clarifying the pathways for further clinical development and regulatory approval of DEP® SN38. This feedback provides
confidence for an Investigational New Drug (IND) application for DEP® SN38. Our partner engagement through ongoing meetings
and conference participation during the six months to December have highlighted the importance of FDA feedback for potential
partners regarding the commercialisation of DEP ® SN38. Additionally, aspects of this feedback are also relevant to the DEP®
cabazitaxel program, for example, the appropriateness of the 505(b)(2) approval pathway for DEP® delivery products
incorporating existing approved actives.
Accelerating Early Asset Development
Starpharma is enhancing its efforts to develop novel DEP® assets and broaden access to its dendrimer platform technology for
drug development through research collaborations and licensing. The company’s key objective is to expand its pipeline of DEP®
assets in early development and improve the efficiency of its early development program. This includes both the company’s
internal development initiatives and its research collaborations.
Starpharma’s preclinical development program includes DEP® radiopharmaceutical candidates targeting the diagnosis and
treatment of HER2 cancers. The company’s research has shown that the DEP® technology can achieve an improved
biodistribution profile compared with large antibody and small molecule delivery of radioisotopes, characterised by high levels of
accumulation in tumours, low uptake in radio-sensitive organs such as the kidney, and relatively fast clearance from the blood. The
data generated indicate that DEP® is a promising, versatile, and multifunctional platform for customising precision
radiopharmaceuticals for cancer imaging and therapeutic applications.
During the period, Starpharma made important progress in the DEP® radiopharmaceuticals program to optimise our candidates
to take forward. A number of preclinical evaluations were completed to assess and continue to enhance the profiles of the DEP®
HER2-radiodiagnostic and DEP® HER2-radiotherapeutic candidates. Starpharma aims to develop radiopharmaceutical products
that offer optimal pharmacokinetic and biodistribution profiles while accurately assessing the HER2 status of tumours throughout
the body.
As Starpharma continues the iterative development of its assets, the company has gathered input from key opinion leaders (KOLs)
and progressed discussions with potential clinical sites and contract research organisations (CROs) to ensure the company can
start a first-in-patient clinical trial of its DEP® radiopharmaceutical candidates as efficiently as possible.
Additionally, the early-stage DEP® radiopharmaceuticals data presented at various conferences during the period has generated
considerable interest in collaborative opportunities from a range of companies in the radiopharmaceuticals sector, both locally
and internationally, who are looking to optimise the biodistribution profiles of their own radiotheranostic candidates.
Starpharma’s early-stage research also includes targeted dendrimer-drug conjugates, which combine targeting moieties, such
as antibodies or smaller antibody fragments, with dendrimers to further enhance the delivery of cytotoxic drugs. In parallel with
pursuing Starpharma’s DEP® radiopharmaceuticals program, Starpharma was also developing a HER2-targeted drug dendrimer
conjugate, but considering the ongoing advancements with its radiopharmaceutical candidates, the company decided to shift its
focus during this period to explore targets other than HER2. The company has also expanded its early-stage research pipeline
during the period.
Starpharma’s DEP® research collaborations include programs with several partners, including Genentech, MSD, and Petalion
Therapeutics. These collaborations typically involve partner companies evaluating the utility of Starpharma’s dendrimer
technology in combination with their own molecules and technologies for novel applications or using the DEP® platform to
develop novel assets, as is the case for Petalion.
During the period, Starpharma made good progress in its ongoing DEP® partnerships while also actively engaging with potential
new collaborators. The company increased its internal chemistry resources to support the growing needs of some of its partners.
The ultimate goal of these research collaborations is to develop valuable novel assets for areas of high unmet medical need.
Starpharma aims to convert these assets into technology licenses that generate value for its shareholders.
The company also has partnerships with several research institutions, including the Commonwealth Scientific and Industrial
Research Organisation (CSIRO), Monash Institute of Pharmaceutical Sciences (MIPS), and the Australian Research Council’s (ARC)
Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR). Starpharma collaborates with these
organisations to explore the application of dendrimers in high-interest areas for the scientific community, such as the mRNA
project with CSIRO. These collaborations are valuable in generating substantial data and validation for the company’s innovative
dendrimer technology in novel medical applications.
Interim Report – 31 December 2024
Starpharma Holdings Limited
3
On 26 November 2024, Starpharma informed shareholders about the decision to terminate its partnership with AstraZeneca. After
nearly 18 months of inactivity, both parties agreed to end the agreement. Starpharma made this decision to clarify the status of
the partnership for investors and to allow Starpharma to pursue other opportunities.
Building Long-Term Sustainability
Starpharma is focused on increasing sustainable revenues and managing costs effectively. The company’s key focus areas in the
short term include increasing revenue, improving efficiency, and reducing costs to support our longer-term self-sustaining goal.
Increasing revenues from VivaGel® BV and Viraleze™ is a key objective. During the period, Starpharma has closely collaborated
with ITROM Pharmaceutical Group, its distribution partner for VivaGel® BV in the Middle East and North Africa, to ensure a
successful product launch in Saudi Arabia and the United Arab Emirates (UAE). Starpharma is currently in the process of
manufacturing the product, which will be supplied to ITROM in March 2025, with the product launch expected to follow shortly
thereafter. ITROM will support the launch through marketing efforts aimed at both consumers and local medical professionals.
Starpharma’s partner, Aspen, continues to market VivaGel® BV in Australia and New Zealand, and the company has also engaged
in discussions with a number of companies interested in marketing VivaGel® BV across Europe and Asia.
Over the past six months, Starpharma has implemented several digital marketing initiatives for Viraleze™ aimed at enhancing the
product’s profile and increasing online sales. These initiatives included launching a new website, improving brand positioning, and
social media marketing.
During the period, Starpharma achieved regulatory certification under the new European Union (EU) Medical Device Regulations
for Viraleze™. The new EU MDR classifications require medical device manufacturers to demonstrate compliance with essential
requirements, including a greater emphasis on clinical evidence, and to undergo a new conformity assessment process with a
European-based Notified Body to ensure the safety and performance of medical devices. Starpharma has now successfully
obtained EU MDR certification for both VivaGel® BV and Viraleze™, confirming that both products meet the safety and
performance standards established by EU regulatory authorities.
In October 2024, Starpharma announced its decision to withdraw the application for marketing authorisation of the SPL7013
Nasal Spray in Australia. The decision followed more than three years of application and review processes that required significant
internal resources. After careful consideration and external regulatory legal advice, the Board and leadership team determined
that withdrawing the application was in the best interest of shareholders. This allows the company to focus on Viraleze™ in
markets where the product is already approved and on its high-priority DEP® platform programs.
Review of Financials
Income statement
Revenue
Cost of goods sold
31 December 2024
$’000
31 December 2023
$’000
2,427
8,025
(348)
(201)
Research and product development expense (net of R&D tax incentive)
(4,337)
(5,263)
Commercial and regulatory operating expense
(1,553)
(1,516)
Corporate, administration and finance expense
(1,581)
(2,079)
Loss for the period
(5,392)
(1,034)
Income statement
The reported loss for the half-year ended 31 December 2024 was $5,392,000 (31 December 2023: $1,034,000). The prior halfyear loss included nonrecurring revenue of $6,553,000 from the commercial settlement and termination of the VivaGel® BV
license and supply agreement with Mundipharma.
Revenue for the half-year was $2,427,000, comprising product sales, royalty, and research revenue from commercial partners of
$1,888,000 (31 December 2023: $644,000, excluding the Mundipharma settlement), and interest income on cash invested of
$539,000 (31 December 2023: $828,000). Excluding the effects of the Mundipharma settlement in the prior period, the half-year
revenue has increased 65% over the prior period, primarily due to research revenue from Petalion Therapeutics Limited and
increased revenue from the sale of Viraleze™ and VivaGel® BV.
Research and product development expenses was $4,337,000 (31 December 2023: $5,263,000) and includes the costs of the
internal DEP® drug delivery programs, including DEP® SN38, DEP® cabazitaxel and DEP® radiotheranostics. The decrease in expense
from the prior half-year reflects the completion of the DEP ® cabazitaxel, DEP® docetaxel, and Viraleze™ clinical programs. A contra
expense of $1,976,000 (31 December 2023: $3,091,000) has been recorded to research and product development expense for
amounts receivable under the Australian Government’s R&D Tax Incentive program.
Commercial and regulatory operating expense includes expenditure related to commercialisation of both VivaGel ® / Viraleze™
and DEP® portfolios, including business development, marketing, regulatory, supply chain and quality assurance activities.
Corporate, administration and finance expense includes corporate costs, gains/losses on foreign currency held, and interest
expense on borrowings. The decrease in expense from the prior half-year reflects cost reduction initiatives implemented.
Interim Report – 31 December 2024
Starpharma Holdings Limited
4
Balance sheet
At 31 December 2024, the Group’s cash position was $20,277,000 (June 2024: $23,360,000). Trade and other receivables of
$3,643,000 (June 2024: $7,151,000) includes $1,976,000 (30 June 2024: $5,527,000) receivable from the Australian Government
under the R&D tax incentive program. Trade and other payables of $2,655,000 (June 2024: $4,013,000) have decreased primarily
due to lower accruals associated with expenditure on research programs.
Statement of cash flows
Net operating cash outflows for the half-year were $1,996,000 (31 December 2023: $2,098,000 inflow) and include the receipt of
the $5,527,000 R&D tax incentive. Net cash outflows fr
Share your feedback
Discover